A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy
Latest Information Update: 30 Jan 2025
At a glance
- Drugs Mezagitamab (Primary)
- Indications IgA nephropathy
- Focus Adverse reactions
- Sponsors Takeda
Most Recent Events
- 08 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2022 Status changed from not yet recruiting to recruiting.
- 18 Oct 2022 Planned initiation date changed from 20 Oct 2022 to 17 Oct 2022.